Which has stronger valuation & earnings, GRFS or VOR?

Grifols has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $7.42B 0.72 $454.82M $0.19 41.47 Vor Biopharma N/A N/A N/A N/A N/A

Which has preferable earnings & valuation, VOR or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A ACADIA Pharmaceuticals $1.07B 4.48 $391M $2.22 12.55

Does the media favor VOR or ACAD?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for ACADIA Pharmaceuticals and 6 mentions for Vor Biopharma. ACADIA Pharmaceuticals' average media sentiment score of 1.56 beat Vor Biopharma's score of 0.93 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, VOR or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is VOR or PBLS more profitable?

Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Parabilis Medicines N/A N/A N/A

Does the media favor VOR or PBLS?

In the previous week, Vor Biopharma and Vor Biopharma both had 6 articles in the media. Parabilis Medicines' average media sentiment score of 1.43 beat Vor Biopharma's score of 0.93 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, VOR or DYN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A

Is VOR or DYN more profitable?

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Dyne Therapeutics N/A -64.30% -50.33%

Does the media prefer VOR or DYN?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for Dyne Therapeutics and 6 mentions for Vor Biopharma. Dyne Therapeutics' average media sentiment score of 1.46 beat Vor Biopharma's score of 0.93 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, VOR or EWTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is VOR or EWTX more profitable?

Vor Biopharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Edgewise Therapeutics N/A -39.01% -36.96%

Does the media favor VOR or EWTX?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Edgewise Therapeutics and 6 mentions for Vor Biopharma. Edgewise Therapeutics' average media sentiment score of 1.20 beat Vor Biopharma's score of 0.93 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vor Biopharma (VOR) Competitors

$24.24 -0.52 (-2.10%)

As of 09/3/2026 04:00 PM Eastern

Compare

VOR vs. GRFS, ACAD, PBLS, DYN, and EWTX

Should you buy Vor Biopharma stock or one of its competitors? Vor Biopharma's main competitors and comparable companies include Grifols (GRFS), ACADIA Pharmaceuticals (ACAD), Parabilis Medicines (PBLS), Dyne Therapeutics (DYN), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vor Biopharma compare to Grifols?

Grifols (NASDAQ:GRFS) and Vor Biopharma (NASDAQ:VOR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Grifols has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$7.42B	0.72	$454.82M	$0.19	41.47
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Grifols currently has a consensus target price of $10.00, suggesting a potential upside of 26.90%. Vor Biopharma has a consensus target price of $43.38, suggesting a potential upside of 78.94%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Grifols has a net margin of 5.54% compared to Vor Biopharma's net margin of 0.00%. Grifols' return on equity of 6.21% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Vor Biopharma	N/A	N/A	N/A

97.3% of Vor Biopharma shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Vor Biopharma had 6 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Vor Biopharma and 0 mentions for Grifols. Vor Biopharma's average media sentiment score of 0.93 beat Grifols' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Grifols	Neutral
Vor Biopharma	Positive

Summary

Vor Biopharma beats Grifols on 9 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Vor Biopharma (NASDAQ:VOR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Vor Biopharma has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Vor Biopharma's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Vor Biopharma currently has a consensus price target of $43.38, suggesting a potential upside of 78.94%. ACADIA Pharmaceuticals has a consensus price target of $34.36, suggesting a potential upside of 23.33%. Given Vor Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Vor Biopharma is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for ACADIA Pharmaceuticals and 6 mentions for Vor Biopharma. ACADIA Pharmaceuticals' average media sentiment score of 1.56 beat Vor Biopharma's score of 0.93 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
ACADIA Pharmaceuticals	$1.07B	4.48	$391M	$2.22	12.55

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Vor Biopharma on 8 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Parabilis Medicines?

Vor Biopharma (NASDAQ:VOR) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Vor Biopharma currently has a consensus price target of $43.38, indicating a potential upside of 78.94%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 2.25%. Given Vor Biopharma's higher possible upside, equities research analysts plainly believe Vor Biopharma is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Parabilis Medicines	N/A	N/A	N/A

97.3% of Vor Biopharma shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vor Biopharma and Vor Biopharma both had 6 articles in the media. Parabilis Medicines' average media sentiment score of 1.43 beat Vor Biopharma's score of 0.93 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vor Biopharma beats Parabilis Medicines on 5 of the 7 factors compared between the two stocks.

How does Vor Biopharma compare to Dyne Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Vor Biopharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Dyne Therapeutics had 4 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for Dyne Therapeutics and 6 mentions for Vor Biopharma. Dyne Therapeutics' average media sentiment score of 1.46 beat Vor Biopharma's score of 0.93 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vor Biopharma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Vor Biopharma presently has a consensus target price of $43.38, indicating a potential upside of 78.94%. Dyne Therapeutics has a consensus target price of $34.42, indicating a potential upside of 37.94%. Given Vor Biopharma's higher probable upside, equities research analysts plainly believe Vor Biopharma is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Summary

Vor Biopharma and Dyne Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Vor Biopharma compare to Edgewise Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Vor Biopharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Vor Biopharma currently has a consensus price target of $43.38, indicating a potential upside of 78.94%. Edgewise Therapeutics has a consensus price target of $50.33, indicating a potential upside of 19.98%. Given Vor Biopharma's higher possible upside, research analysts plainly believe Vor Biopharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

97.3% of Vor Biopharma shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 9 mentions for Edgewise Therapeutics and 6 mentions for Vor Biopharma. Edgewise Therapeutics' average media sentiment score of 1.20 beat Vor Biopharma's score of 0.93 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Vor Biopharma has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Summary

Vor Biopharma beats Edgewise Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.46B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	N/A	16.29	12.89	6.14
Net Income	N/A	-$22.72M	$3.47B	$349.01M
7 Day Performance	7.02%	0.34%	0.61%	-0.27%
1 Month Performance	8.94%	8.52%	5.73%	0.68%
1 Year Performance	-37.20%	52.66%	25.37%	14.84%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	2.3771 of 5 stars	$24.24 -2.1%	$43.38 +78.9%	-39.4%	$1.46B	N/A	N/A	140	News Coverage
GRFS Grifols	4.2844 of 5 stars	$7.69 -1.7%	$10.00 +30.0%	-17.8%	$5.23B	$8.51B	40.47	25,247
ACAD ACADIA Pharmaceuticals	4.8259 of 5 stars	$29.11 -2.1%	$34.36 +18.0%	+8.3%	$5.02B	$1.07B	13.11	510	Positive News
PBLS Parabilis Medicines	2.4631 of 5 stars	$39.11 -0.5%	$41.67 +6.5%	N/A	$4.83B	N/A	N/A	N/A	Positive News
DYN Dyne Therapeutics	3.6477 of 5 stars	$25.07 -3.9%	$34.42 +37.3%	+85.1%	$4.68B	N/A	N/A	100	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. GRFS, ACAD, PBLS, DYN, and EWTX

How does Vor Biopharma compare to Grifols?

Summary

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Summary

How does Vor Biopharma compare to Parabilis Medicines?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Summary

How does Vor Biopharma compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. GRFS, ACAD, PBLS, DYN, and EWTX

How does Vor Biopharma compare to Grifols?

Which has stronger valuation & earnings, GRFS or VOR?

Which has more volatility and risk, GRFS or VOR?

Do analysts prefer GRFS or VOR?

Is GRFS or VOR more profitable?

Do insiders and institutionals hold more shares of GRFS or VOR?

Does the media prefer GRFS or VOR?

Summary

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Which has more volatility and risk, VOR or ACAD?

Is VOR or ACAD more profitable?

Do analysts rate VOR or ACAD?

Does the media favor VOR or ACAD?

Which has preferable earnings & valuation, VOR or ACAD?

Do insiders and institutionals hold more shares of VOR or ACAD?

Summary

How does Vor Biopharma compare to Parabilis Medicines?

Do analysts rate VOR or PBLS?

Which has better earnings & valuation, VOR or PBLS?

Is VOR or PBLS more profitable?

Do institutionals and insiders have more ownership in VOR or PBLS?

Does the media favor VOR or PBLS?

Summary

How does Vor Biopharma compare to Dyne Therapeutics?

Which has better valuation and earnings, VOR or DYN?

Is VOR or DYN more profitable?

Does the media prefer VOR or DYN?

Do insiders and institutionals believe in VOR or DYN?

Which has more risk & volatility, VOR or DYN?

Do analysts prefer VOR or DYN?

Summary

How does Vor Biopharma compare to Edgewise Therapeutics?

Is VOR or EWTX more profitable?

Do analysts prefer VOR or EWTX?

Do insiders & institutionals believe in VOR or EWTX?

Does the media favor VOR or EWTX?

Which has higher earnings & valuation, VOR or EWTX?

Which has more risk and volatility, VOR or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools